>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
卡培他滨维持治疗晚期食管-胃交界处腺癌的临床观察
作者:陆斌1  瞿彩平1  孙征1  陆朝云1  华召来2 
单位:1. 扬中市人民医院肿瘤内科, 江苏 扬中 212200;
2. 扬中市肿瘤防治研究所, 江苏 扬中 212200
关键词:食管-胃交界处腺癌 卡培他滨 维持治疗 疾病进展时间 生活质量改善时间 
分类号:R735.2
出版年·卷·期(页码):2017·36·第一期(86-89)
摘要:

目的:观察晚期食管-胃交界处腺癌(AEG)予以卡培他滨联合其他药物化疗后,以卡培他滨单药维持治疗的效果及其安全性。方法:对60例晚期AEG患者予以卡培他滨联合紫杉醇和奥沙利铂方案化疗4~6周期后,将患者随机分为维持治疗组和对照组。维持治疗组予以相同剂量的卡培他滨单药口服维持治疗,对照组仅随访而不予治疗,比较两组疾病进展时间(PFS)、生活质量改善时间和不良反应。结果:维持治疗组与对照组比较,PFS明显延长(11个月vs.7个月),生活质量改善时间明显延长(15.5个月vs.10.5个月),两组常见不良反应发生率差异无统计学意义。结论:卡培他滨能够延长晚期AEG患者的无进展生存期,改善患者生存质量。

Objective:To observe the efficacy and safety of the capecitabine single drug maintenance treatment for adenocarcinoma of esophagogastric junction(AEG),after chemotherapy of the capecitabine combined with other drugs.Methods:Sixty patients with AEG were randomly divided into treatment group and control group after chemotherapy by capecitabine combined with paclitaxel and oxaliplatin for 4 to 6 cycles.Then maintain treatment group was given the same dose of capecitabine for single-agent oral maintenance treatment,the control group only followed-up but no treatment.The progression free survival (PFS),quality of life improved time and adverse reactions between the two groups were compared.Results:Compared with control group,PFS of maintain treatment group was obviously prolonged (11months vs.7months),the quality of life was obviously improved (15.5months vs. 10.5months),common adverse reactions of the two groups had no significant difference.Conclusion:Capecitabine can prolong progression-free survival of patients with advanced AEG and improve patients' quality of life.

参考文献:

[1] SIEGEL R,MA J,ZOU Z,et al.Cancer statistics[J].CA Cancer J Clin,2014,64:9-29.
[2] JIANG X,de GROH M,LIU S,et al.Rising incidence of adenocarcinoma of the lung in Canada[J].Lung Cancer,2012,78:16-22.
[3] 孙燕,马胜林.晚期胃癌药物治疗策略和展望[J].中华肿瘤防治杂志,2010,17(5):395-398.
[4] LORDICK F,OTT K,SENDLER A.Gastric cancer and adenocarcinoma of the esophagogastric junction:principles of neoadjuvant therapy[J].Chirurg,2011,82:968-973.
[5] POPA E C,SHAH M A.Capecitabine in the treatment of esophageal and gastric cancers[J].Expert Opin Investig Drugs,2013,22:1645-1657.
[6] HUANG H,JIANG Z,WANG T,et al.Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer[J].Anticancer Drugs,2012,23:718-723.
[7] SI W,ZHU YY,LI Y,et al.Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer[J].Braz J Med Biol Res,2013,46:1074-1081.
[8] LV H,YAN M,ZHANG M,et al.Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer[J].Chin J Cancer Res,2014,26:692-697.
[9] WADDELL T,GOLLINS S,SOE W,et al.Phase Ⅱ study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer:XelQuali study[J].Cancer Chemother Pharmacol,2011,67:1111-1117.
[10] LI Y H,LUO H Y,WANG F H,et al.Phase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer[J].J Cancer Res Clin Oncol,2010,136:503-510.
[11] QIU M Z,WEI X L,ZHANG D S,et al.Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients:a prospective observation[J].Tumour Biol,2014,35:4369-4375.
[12] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10.
[13] 孙燕,马胜林.晚期胃癌药物治疗策略和展望[J].中华肿瘤防治杂志,2010,17(5):395-398.
[14] 袁笑,郭涛,陆震,等.324例不同年龄段胃癌患者临床病理资料分析[J].安徽医药,2014,18(9):1679-1681.
[15] YUNG-JUE B,YOUNG-WOO K,HAN-KWANG Y,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label,randomised controlled trial[J].Lancet,2012,379(9813):315-321.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405968 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364